<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-topic" /><meta name="keywords" content="Taxanes; Paclitaxel; Docetaxel; Cabazitaxel" /><meta name="IX" content="Taxanes; Paclitaxel; Docetaxel; Cabazitaxel" /><title>Taxanes: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP5550-taxanes.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP5550-taxanes.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP5550-taxanes.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 07 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP5179-malignant-disease-and-immunosuppression.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="PHP5180-cytotoxic-drugs.htm">8.1 Cytotoxic drugs</a> &gt; <a href="PHP5425-other-antineoplastic-drugs.htm">8.1.5 Other antineoplastic drugs</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP17983-vemurafenib.htm" title="Previous: VEMURAFENIB">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP5557-cabazitaxel.htm" title="Next: CABAZITAXEL">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information (3)</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a311007.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Cabazitaxel</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Antineoplastic Agents 10:00</p></div></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a396031.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Docetaxel</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Antineoplastic Agents 10:00</p></div></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a398035.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Paclitaxel</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Antineoplastic Agents 10:00</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts (2)</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/14634-b.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Docetaxel</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: D &gt; Interactions of Docetaxel</p></div></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/2453-y.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Paclitaxel</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: P &gt; Interactions of Paclitaxel</p></div></li></ul><ul><li><h3>British National Formulary (8)</h3></li><li><a href="PHP5557-cabazitaxel.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">CABAZITAXEL</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.1 Cytotoxic drugs &gt; 8.1.5 Other antineoplastic drugs &gt; Taxanes</p></div></li><li><a href="PHP5559-docetaxel.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">DOCETAXEL</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.1 Cytotoxic drugs &gt; 8.1.5 Other antineoplastic drugs &gt; Taxanes</p></div></li><li><a href="PHP5560-docetaxel-non-proprietary.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Docetaxel</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.1 Cytotoxic drugs &gt; 8.1.5 Other antineoplastic drugs &gt; Taxanes &gt; DOCETAXEL</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22taxanes%22%22paclitaxel%22%22docetaxel%22%22cabazitaxel%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (8)</a></li></ul><ul><li><h3>Clarke's Analysis of Drugs and Poisons (2)</h3></li><li><a href="http://www.medicinescomplete.com/mc/clarke/2010/CLK0589.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Docetaxel</a><div class="breadcrumb"><p><strong>Clarke's Analysis of Drugs and Poisons</strong> &gt; Monographs &gt; Alphabetically &gt; D</p></div></li><li><a href="http://www.medicinescomplete.com/mc/clarke/2010/CLK1251.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Paclitaxel</a><div class="breadcrumb"><p><strong>Clarke's Analysis of Drugs and Poisons</strong> &gt; Monographs &gt; Alphabetically &gt; P</p></div></li></ul><ul><li><h3>Handbook on Injectable Drugs (2)</h3></li><li><a href="http://www.medicinescomplete.com/mc/hid/2010/a500003.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Docetaxel</a><div class="breadcrumb"><p><strong>Handbook on Injectable Drugs</strong> &gt; Monographs &gt; D</p></div></li><li><a href="http://www.medicinescomplete.com/mc/hid/2010/a593005.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Paclitaxel</a><div class="breadcrumb"><p><strong>Handbook on Injectable Drugs</strong> &gt; Monographs &gt; P</p></div></li></ul><ul><li><h3>Stability-Indicating HPLC Methods for Drug Analysis (2)</h3></li><li><a href="http://www.medicinescomplete.com/mc/hplc/2008/ch0004s0282.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Docetaxel</a><div class="breadcrumb"><p><strong>Stability-Indicating HPLC Methods for Drug Analysis</strong> &gt; Monographs &gt; D</p></div></li><li><a href="http://www.medicinescomplete.com/mc/hplc/2008/ch0015s0001.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Paclitaxel</a><div class="breadcrumb"><p><strong>Stability-Indicating HPLC Methods for Drug Analysis</strong> &gt; Monographs &gt; P</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference (3)</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/25232-w.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Cabazitaxel</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antineoplastics &gt; Drug Monographs</p></div></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/14634-b.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Docetaxel</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antineoplastics &gt; Drug Monographs</p></div></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/2453-y.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Paclitaxel</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antineoplastics &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index (3)</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/10493.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Cabazitaxel</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; C &gt; CA</p></div></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/03397.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Docetaxel</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; D &gt; DO</p></div></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/06982.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Paclitaxel</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; P &gt; PA</p></div></li></ul><ul><li><h3>Remington: The Science and Practice of Pharmacy (4)</h3></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/c7-sec1-0013.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Volatile Oils, Resins, and Miscellaneous Isoprenoids</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 1: The Science of Pharmacy &gt; Section 2: Pharmaceutical Chemistry &gt; 7 Natural Products</p></div></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/mono-C1.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Cabazitaxel</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 3: Pharmaceutical and Medicinal Agents &gt; C</p></div></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/mono-D96.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Docetaxel</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 3: Pharmaceutical and Medicinal Agents &gt; D</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22taxanes%22%22paclitaxel%22%22docetaxel%22%22cabazitaxel%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (4)</a></li></ul><ul><li><h3>Stockley's Drug Interactions (4)</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E2E0E56E3E0R0D1806.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Cabazitaxel</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; C</p></div></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E0E0E10E3E0R0D1578.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Docetaxel</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; D</p></div></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E0E0E14E3E0R0D645.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Paclitaxel</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; P</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22taxanes%22%22paclitaxel%22%22docetaxel%22%22cabazitaxel%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (4)</a></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1>Taxanes</h1><?highlighter on?><div id="pC" class="jN"><p id="PHP5551"><strong>Paclitaxel </strong> is a member of the taxane group of drugs. It is given by <em>intravenous infusion</em>. Paclitaxel given with carboplatin or cisplatin is used for the treatment of ovarian cancer (see <a title="target-block: paclitaxel for ovarian cancer nice guidance" href="PHP5487-platinum-compounds.htm#PHP5495">NICE guidance</a>); the combination is also considered appropriate for women whose ovarian cancer is initially considered inoperable. Paclitaxel is also licensed for the secondary treatment of metastatic breast cancer. There is limited evidence to support its use in non-small cell lung cancer. Routine premedication with a corticosteroid, an antihistamine and a histamine H<sub>2</sub>-receptor antagonist is recommended to prevent severe hypersensitivity reactions; hypersensitivity reactions may occur rarely despite premedication, although more commonly only bradycardia or asymptomatic hypotension occur.</p><p>Other side-effects of paclitaxel include myelosuppression, peripheral neuropathy, and cardiac conduction defects with arrhythmias (which are nearly always asymptomatic). It also causes alopecia and muscle pain; nausea and vomiting is mild to moderate.</p><p id="PHP5553"><strong>Docetaxel</strong> is licensed for use in locally advanced or metastatic breast cancer and non-small cell lung cancer resistant to other cytotoxic drugs or for initial chemotherapy in combination with other cytotoxic drugs. It is also licensed for hormone-resistant prostate cancer, for use with other cytotoxic drugs for gastric adenocarcinoma and head and neck cancer, and for adjuvant treatment of operable node-positive and operable node-negative breast cancer. Its side-effects are similar to those of paclitaxel but persistent fluid retention (commonly as leg oedema that worsens during treatment) can be resistant to treatment; hypersensitivity reactions also occur. Pretreatment with dexamethasone by mouth is recommended for reducing fluid retention and hypersensitivity reactions.</p><p>For the role of taxanes in the treatment of breast cancer, see <a title="BNF:sub-sub-section: Breast cancer" href="PHP5747-breast-cancer.htm">section 8.3.4.1</a>.</p><p>The <a title="target-block: NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has advised that docetaxel (<em>Taxotere</em>®) in combination with cisplatin and fluorouracil is accepted for restricted use within NHS Scotland for the induction treatment of patients with unresectable (May 2007) and resectable (June 2008) locally advanced squamous cell carcinoma of the head and neck.</p><div class="cI"><h3 class="cT">NICE guidance (paclitaxel, pegylated liposomal doxorubicin and topotecan for second-line or subsequent treatment of advanced ovarian cancer)</h3><p>See <a title="target-block: paclitaxel, doxorubicin, topotecan nice guidance" href="PHP5487-platinum-compounds.htm#PHP5496">Platinum Compounds</a></p></div><div class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (June 2006)</h3><p>Docetaxel is an option for hormone-refractory metastatic prostate cancer and a Karnofsky score of at least 60% [Karnofsky score is a measure of the ability to perform ordinary tasks].</p></div><p id="PHP5556"><strong>Cabazitaxel</strong>, in combination with prednisone or prednisolone, is licensed for the treatment of hormone refractory metastatic prostate cancer in patients who have previously been treated with a docetaxel-containing regimen. Routine premedication with a corticosteroid, an antihistamine, and a histamine H<sub>2</sub>-receptor antagonist is recommended to prevent severe hypersensitivity reactions. Hypersensitivity reactions are common.</p><p>Other side-effects of cabazitaxel include weight changes, diarrhoea, constipation, abdominal pain, dyspepsia, gastroesophageal reflux, haemorrhoids, rectal haemorrhage, taste disturbance, dry mouth, chest pain, atrial fibrillation, tachycardia, hypertension, hypotension, flushing, oedema, dyspnoea, cough, peripheral neuropathy, paraesthesia, hypoesthesia, anxiety, confusion, dizziness, headache, malaise, vertigo, chills, hyperglycaemia, urinary retention, urinary incontinence, renal disorders (fatal cases of renal failure reported), dehydration, electrolyte disturbances, sciatica, arthralgia, muscle spasm, myalgia, increased lacrimation, tinnitus, dry skin, erythema.</p><div class="cI"><p class="cAE">NICE guidance</p> <h3 class="cT">Cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen (May 2012)</h3><p id="PHP18374">Cabazitaxel in combination with prednisone or prednisolone is <strong>not</strong> recommended for the treatment of hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.</p><p>Patients currently receiving cabazitaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen should have the option to continue treatment until they and their clinicians consider it appropriate to stop.</p> </div></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP5557-cabazitaxel"><a href="PHP5557-cabazitaxel.htm" title="CABAZITAXEL">CABAZITAXEL</a></li><li id="_PHP5559-docetaxel"><a href="PHP5559-docetaxel.htm" title="DOCETAXEL">DOCETAXEL</a></li><li id="_PHP5562-paclitaxel"><a href="PHP5562-paclitaxel.htm" title="PACLITAXEL">PACLITAXEL</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP17983-vemurafenib.htm">Previous: VEMURAFENIB</a> | <a class="top" href="PHP5550-taxanes.htm#">Top</a> | <a accesskey="]" href="PHP5557-cabazitaxel.htm">Next: CABAZITAXEL</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>